Acorda Therapeutics Partners With Cardinal Health, Inc. To Expand Sales Force For Zanaflex Capsules(TM)

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Nov. 10, 2005--Acorda Therapeutics announced today that it has entered into an agreement with the Contract Sales and Services business of Cardinal Health (NYSE: CAH) Pharmaceutical Technologies and Services segment to expand the sales force for Acorda's Zanaflex Capsules(TM) (tizanidine hydrochloride) with approximately 160 contract sales representatives to address the primary care market.

Back to news